PET and PET/CT in the Management of Thyroid Cancer

Methods in Molecular Biology

Volumn 727, Issue , 2011, Pages 205-224

  Basu, Sandip ^a,b   Urhan, Muammer ^c   Rosenbaum, Joshua ^a   Alavi, Abass ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b TATA MEMORIAL HOSPITAL   (India)

^c GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

Differentiated thyroid carcinoma; Medullary carcinoma of thyroid; PET; PET CT; Thyroid carcinoma; Thyroid lymphoma

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CARCINOMA; HUMAN; LYMPHOMA; METHODOLOGY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; THYROID GLAND; THYROID TUMOR;

CARCINOMA; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYROID GLAND; THYROID NEOPLASMS;

EID: 79956306662     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-062-1_12     Document Type: Chapter

References (82)

1. Cohen, M.S., Arslan, N., Dehdashti, F., et al. (2001) Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucosepositron emission tomography. Surgery 130(6), 941–6.
2. Kang, K.W., Kim, S.K., Kang, H.S., et al. (2003) Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88(9), 4100–4.
3. Kim, T.Y., Kim, W.B., Ryu, J.S., et al. (2005) 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 115(6), 1074–8.
4. Are, C., Hsu, J.F., Schoder, H., et al. (2007) FDG-PET detected thyroid incidentalomas: need for further investigation. Ann Surg Oncol 14(1), 239–47.
5. Kurata, S., Ishibashi, M., Hiromatsu, Y., et al. (2007) Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDGPET: prevalence of thyroid cancer and Hashimoto’s thyroiditis. Ann Nucl Med 21(6), 325–30.
6. Chen, Y.K., Ding, H.J., Chen, K.T., et al. (2005) Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res 25(2B), 1421–6.
7. Yi, J.G., Marom, E.M., Munden, R.F., et al. (2005) Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Radiology 236(1), 271–5.
8. Choi, J.Y., Lee, K.S., Kim, H.J., et al. (2006) Focal thyroid lesions incidentally identified by integrated 18FFDG PET/CT: clinical significance and improved characterization. J Nucl Med 47(4), 609–15.
9. Chu, Q.D., Connor, M.S., Lilien, D.L., et al. (2006) Positron emission tomography (PET) positive thyroid incidentaloma: the risk of malignancy observed in a tertiary referral center. Am Surg 72(3), 272–5.
10. King, D.L., Stack, B.C. Jr., Spring, P.M., et al. (2007) Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas. Otolaryngol Head Neck Surg 137(3), 400–4.
11. Bogsrud, T.V., Karantanis, D., Nathan, M.A., et al. (2007) The value of quantifying 18FFDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 28(5), 373–81.
12. Nam, S.Y., Roh, J.L., Kim, J.S., et al. (2007) Focal uptake of (18)F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol (Oxf) 67(1), 135–9.
13. Boerner, A.R., Voth, E., Theissen, P., et al. (1998) Glucose metabolism of the thyroid in Graves’ disease measured by F-18fluorodeoxyglucose positron emission tomography. Thyroid 8, 765–72.
14. Boerner, A.R., Voth, E., Theissen, P., et al. (2000) Glucose metabolism of the thyroid in autonomous goiter measured by F-18-FDGPET. Exp Clin Endocrinol Diabetes 108, 191–6.
15. Karantanis, D., Bogsrud, T.V., Wiseman, G.A., et al. (2007) Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med 48, 896–901.
16. Basu, S., Li, G., Bural, G., Alavi, A. (2008) Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility. Acta Radiol 16, 1–4.
17. Burguera, B., Gharib, H. (2000) Thyroid incidentalomas: prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am 29(1), 187–203.
18. Nakhjavani, M.K., Gharib, H., Goellner, J.R., et al. (1997) Metastasis to the thyroid gland: a report of 43 cases. Cancer 79(3), 574–8.
19. Basu, S., Alavi, A. (2007) Metastatic malignant melanoma to the thyroid gland detected by FDG-PET imaging. Clin Nucl Med 32(5), 388–9.
20. van Tol, K.M., Jager, P.L., Piers, D.A., et al. (2002) Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 12(5), 381–7.
21. Chin, B.B., Patel, P., Cohade, C., et al. (2004) Recombinant human thyrotropin stimulation of fluoro-d-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 89(1), 91–5.
22. Parkin, M.D., Pisani, P., Ferlay, J. (1999) Global cancer statistics. Cancer J Clin 49, 33–64.
23. Hundahl, S.A., Fleming, I.D., Fremgen, A.M., et al. (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, ’85–’95. Cancer 83, 2638–48.
24. Iwata, M., Kasagi, K., Misaki, T., et al. (2004) Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPECT, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 31(4), 491–8.
25. Chung, J-K, So, Y., Lee, J.S., et al. (1999) Value of FDG-PET in papillary thyroid carcinoma with negative 131-I whole-body scan. J Nucl Med 40, 986–92.
26. Yeo, J.S., Chung, J.K., So, Y., et al. (2001) F-18-fluoro-deoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 23, 94–103.
27. Nahas, Z., Goldenberg, D., Fakhry, C., et al. (2005) The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 115, 237–43.
28. Hall, N., Kloos, R.T. (2007) PET Imaging in differentiated thyroid cancer: where does it fit and how do we use it. Arq Bras Endocrinol Metabol 51(5), 793–805.
29. Urhan, M., Mavi, A., Alavi, A., Nanni, C. (2008) Positron emission tomography and thyroid cancer. PET Clin 2, 295–304.
30. Joensuu, H., Ahonen, A. (1987) Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 28, 910–4.
31. Cohen, J.B., Kalinyak, J.E., McDougall, I.R. (2003) Modern management of differentiated thyroid cancer. Cancer Biother Radiopharm 18(5), 689–705.
32. Feine, U., Lietzenmayer, R., Hanke, J.P., Held, J., Wohrle, H., Muller-Schauenburg, W. (1996) Fluorine-18-FDG and iodine-131iodide uptake in thyroid cancer. J Nucl Med 37, 1468–72.
33. 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7, 327–35.
34. Conti, P.S., Durski, J.M., Bacqai, F., Grafton, S.T., Singer, P.A. (1999) Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9, 797–804.
35. 131I scan. J Nucl Med 42, 71–6.
36. Grunwald, F., Kalicke, T., Feine, U., et al. (1999) Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26, 1547–52.
37. McDougal, I.R., Davidson, J., Segall, S.M. (2001) Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun 22, 485–92.
38. van Tol, K.M., Jager, P.L., Piers, D.A., et al. (2002) Better yield of (18)fluorodeoxyglucose positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 715(12), 381–7.
39. Moog, F., Linke, R., Manthey, N., et al. (2000) Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41, 1989–95.
40. Petrich, T., Borner, A.R., Weckesser, E., et al. (2001) Follow-up of thyroid cancer patients using rhTSH: preliminary results. Nuklearmedizin 40, 7–14.
41. Palmedo, H., Bucerius, J., Joe, A., et al. (2006) Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47, 616–24.
42. Zoller, M., Kohlfuerst, S., Igerc, I., et al. (2007) Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality. Eur J Nucl Med Mol Imaging 34, 487–95.
43. Iagaru, A., Kalinyak, J.E., McDougall, I.R. (2007) F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 32, 690–5.
44. 18F-FDG PET/CT in patients with suspected recurrent or metastatic welldifferentiated thyroid cancer. J Nucl Med 48, 221–6.
45. 131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84, 2291–302.
46. Grünwald, F., Menzel, C., Bender, H., et al. (1998) Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39, 1903–6.
47. Schonberger, J., Ruschhoff, J., Grimm, D., et al. (2002) Glucose transporter-1 gene expression is related to thyroid neoplasm with an unfavorable prognosis: an immunohistochemical study. Thyroid 12, 747–54.
48. Lowe, V.J., Mullan, B.P., Hay, I.D., et al. (2003) 18F-FDG PET of patients with Hürthle cell carcinoma. J Nucl Med 44(9), 1402–6.
49. 18F]fluoro-2deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91, 498–505.
50. Reimer, S., Adler, L.P., Bloom, A.D. (1998) Prospective evaluation of PET-FDG in FNA indeterminate thyroid nodules. J Nucl Med 39, 123.
51. Geus-Oei, L.F., Pieters, G.F., Bonenkamp, J.J., et al. (2006) 18FFDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med 47, 770–5.
52. Kim, J.M., Ryu, J.S., Kim, T.Y., et al. (2007) 18F-luorodeoxyglucosepositron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab 92(5), 1630–4.
53. Kresnik, E., Gallowitsch, H.J., Mikosch, P., et al. (2003) Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 133, 294–9.
54. Robbins, R.J., Hill, R.H., Wang, W., et al. (2000) Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 10, 177–83.
55. Erdi, Y.E., Macapinlac, H.A., Larson, S.M., et al. (1999) Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Positron Imaging 2, 41–6.
56. Schirrmeister, H., Guhlman, A., Elsner, K., et al. (1999) Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18-F PET. J Nucl Med 40, 1623–9.
57. Eschmann, S.M., Reischl, G., Bilger, K., et al. (2002) Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 29, 760–7.
58. Pentlow, K.S., Graham, M.C., Lambrecht, R.M., et al. (1991) Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys 18, 357–66.
59. Pentlow, K.S., Graham, M.C., Lambrecht, R.M., et al. (1996) Quantitative imaging of iodine-124 with PET. J Nucl Med 37, 1557–62.
60. Rault, E., Vandenberghe, S., Van Holen, R., et al. (2007) Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131). Cancer Biother Radiopharm 22, 423–30.
61. Freudenberg, L.S., Antoch, G., Jentzen, W., et al. (2004) Value of I-124-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 14, 2092–8.
62. Freudenberg, L.S., Jentzen, W., Gorges, R., et al. (2007) I-124-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 46, 121–8.
63. Freudenberg, L.S., Jentzen, W., Marlowe, R.J., et al. (2007) 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer. Exp Clin Endocrinol Diabetes 115, 690–3.
64. Sgouros, G., Kolbert, K.S., Sheikh, A., et al. (2004) Patient-specific dosimetry for I-131 thyroid cancer therapy using I-124 PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45, 1366–72.
65. Kolbert, K.S., Pentlow, K.S., Pearson, J.R., et al. (2007) Prediction of absorbed dose to normal organs in thyroid cancer patients treated with I-131 by use of I-124 PET and 3-dimensional internal dosimetry software. J Nucl Med 48, 143–9.
66. Ansell, S.M., Grant, C.S., Habermann, T.M. (1999) Primary thyroid lymphoma. Semin Oncol 26, 316–23.
67. Honing, M.L., Seldenrijk, C.A., de Maat, C.E. (1998) Primary thyroid lymphoma. Neth J Med 52, 75–8.
68. Derringer, G.A., Thompson, L.D., Frommelt, R.A., et al. (2000) Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol 24, 623–39.
69. Ruggiero, F.P., Frauenhoffer, E., Stack, B.C. (2005) Thyroid lymphoma: a single institution’s experience. Otolaryngol Head Neck Surg 133, 888–96.
70. Kossev, P., Livolsi, V. (1999) Lymphoid lesions of the thyroid: review in light of the revised European–American lymphoma classification and upcoming World Health Organization classification. Thyroid 9, 1273–80.
71. Lin, E.C. (2007) FDG PET/CT for assessing therapy response in primary thyroid lymphoma. Clin Nucl Med 32(2), 152–3.
72. Brandt-Mainz, K., Muller, S.P., Gorges, R., et al. (2000) The value of F-18 FDG PET in patients with medullary thyroid cancer. Eur J Nucl Med 27, 490–6.
73. Szakall, S. Jr., Esik, O., Balzik, G., et al. (2002) F-18-PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43(1), 66–71.
74. de Groot, J.W., Links, T.P., Jager, P.L., et al. (2004) Impact of F-18 fluoro-2-deoxy-dglucose positron emission tomography (FDGPET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11(8), 786–94.
75. Rubello, D., Rampin, L., Nanni, C., et al. (2008) The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol 34(5), 581–6.
76. Musholt, T.J., Musholt, P.B., Dehdashti, F., et al. (1997) Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 122, 1049–60.
77. Koopmans, K.P., de Groot, J.W., Plukker, J.T., et al. (2008) 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 49(4), 524–31.
78. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 30, 689–94.
79. 18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 34, 1604–9.
80. Grewal, R.K., Lubberink, M., Pentlow, K.S., Larson, S.M. (2007) The Role of Iodine-124Positron Emission Tomography Imaging in the Management of Patients with Thyroid Cancer. PET Clinics 2(3), 313–20.
81. Urhan, M., Alavi, A., Nanni, C. (2007) The Evolving Role of Positron Emission Tomography in Patients with Medullary Thyroid Carcinoma. PET Clinics 2(3), 305–11.
82. Chen, W., Li, G., Parsons, M., Zhuang, H., Alavi, A. (2007) Clinical Significance of Incidental Focal Versus Diffuse Thyroid Uptake on FDG-PET Imaging. PET Clinics 2(3), 321–29.